Ischemic colitis

Unum provides extra coverage for pregnancy complications, added cancer benefits and life-threatening illnesses

Retrieved on: 
Monday, July 17, 2023
Exercise, Insurance, Radiation, NOT, Transience, Pre-eclampsia, Financial services, Marketing, NICU, Pulmonary embolism, Supplement, Policy, Bone marrow, Cancer, TIA, ME, UIC, Research, UNM, Transient ischemic attack, New York State Department of Financial Services, Investment, Critical illness insurance, HR, Diagnosis, American Cancer Society, Hospice and palliative medicine, Health, Ischemic colitis, Provident Life & Trust Company, NYSE, Life insurance, Health insurance, Dietary supplement, Unum

Unum's critical illness insurance, which provides benefits upon diagnosis of a serious illness or medical event, is adding more financial protection for policyholders and their families.

Key Points: 
  • Unum's critical illness insurance, which provides benefits upon diagnosis of a serious illness or medical event, is adding more financial protection for policyholders and their families.
  • "Providing coverage that includes enhanced protection for critical illnesses is an investment in the well-being and security for employees, said Tom Dupuis, VP of Products.
  • According to the American Cancer Society, there were 1.9 million new cancer cases diagnosed in the U.S. in 2022.
  • Unum has introduced a new cancer benefit that provides ongoing support and coverage.

ZELNORM® (tegaserod) Notice of Withdrawal from Market

Retrieved on: 
Thursday, June 30, 2022
FDA, Patient, Suicidal ideation, Caregiver, Akwa Ibom State Association of Nigeria, USA Inc., Medical information, Behavior, Workforce, MACE, Stroke, VSL, Cerefolin, Depression, Syncope, Ischemic colitis, Hypotension, Risk, Health professional, Hypovolemia, Dysentery, Health status of Asian Americans, Counsel, Diarrhea, TIA, Angina, GI, Safety, Coronary artery disease, MI, EST, NDA, Pharmaceutical industry, Pamlab

COVINGTON, La., June 30, 2022 /PRNewswire/ --Alfasigma USA, Inc. announces the withdrawal of the NDA for ZELNORM (tegaserod) effective June 30th.

Key Points: 
  • COVINGTON, La., June 30, 2022 /PRNewswire/ --Alfasigma USA, Inc. announces the withdrawal of the NDA for ZELNORM (tegaserod) effective June 30th.
  • Our decision to remove ZELNORM (tegaserod) from the market is strictly a business decision.
  • Patients will continue to have access to ZELNORM (tegaserod) for as long as the existing supply of product remains in the trade channel.
  • Ischemic Colitis:Ischemic colitis and other forms of intestinal ischemia have been reported postmarketing in patients receiving ZELNORM (R).

RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans

Retrieved on: 
Wednesday, December 1, 2021
Patient, Clarithromycin, Ketoconazole, Anxiety, Diverticulitis, Brain, OIC, Nausea, Chills, Medicare, Multiple sclerosis, Cancer, Traffic barrier, PAMORA, Headache, GI, Flatulence, Alzheimer's disease, Abdominal pain, Chronic pain, Obstruction, Ischemic colitis, Nasdaq, Risk, Hyperhidrosis, Diarrhea, Adult, Irritability, Yawn, Methadone, Medicare Part D, Formulary, CYP3A4, Vomiting, TEL, Redhill, Opioid, Excipient, Diverticular disease, Bevacizumab, Analgesic, Epilepsy, Pharmaceutical industry

"This important new listing for Movantik, the market-leading PAMORA for opioid-induced constipation, as a preferred and unrestricted brand on a major National Medicare Part D formulary provides that access to more than 10 million more Americans covered by this formulary.

Key Points: 
  • "This important new listing for Movantik, the market-leading PAMORA for opioid-induced constipation, as a preferred and unrestricted brand on a major National Medicare Part D formulary provides that access to more than 10 million more Americans covered by this formulary.
  • Patients with known or suspected gastrointestinal (GI) obstruction and patients at risk of recurrent obstruction, due to the potential for GI perforation.
  • Patients with a known serious or severe hypersensitivity reaction to Movantik or any of its excipients.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

Retrieved on: 
Tuesday, September 7, 2021

said Dr. Lynn Webster, Pain Researcher and Clinician and Senior Fellow at the Center of U.S. Policy.

Key Points: 
  • said Dr. Lynn Webster, Pain Researcher and Clinician and Senior Fellow at the Center of U.S. Policy.
  • "There has been a shift in clinical practice to try to reduce doses of opioids used to treat chronic pain.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.
  • You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at1-833-ADRHILL(1-833-237-4455)or FDA at1-800-FDA-1088or www.fda.gov/medwatch .

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

Retrieved on: 
Tuesday, September 7, 2021

TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation at PAINWeek 2021 of three new analyses of Movantik® (naloxegol) Phase 3 study data demonstrating rapid onset of action and sustained and predictable improvement of key symptoms associated with opioid-induced constipation (OIC) in both a subgroup of patients aged ≥ 65 and across both low and high dose opioid therapy.

Key Points: 
  • said Dr. Lynn Webster, Pain Researcher and Clinician and Senior Fellow at the Center of U.S. Policy.
  • "There has been a shift in clinical practice to try to reduce doses of opioids used to treat chronic pain.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.
  • You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at1-833-ADRHILL(1-833-237-4455)or FDA at1-800-FDA-1088or www.fda.gov/medwatch .